Corcept Therapeutics Incorporated (NASDAQ:CORT) Given Consensus Rating of “Buy” by Analysts

Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) have been assigned a consensus rating of “Buy” from the five analysts that are covering the company, Marketbeat Ratings reports. Five analysts have rated the stock with a buy rating. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $88.25.

CORT has been the topic of a number of research analyst reports. Canaccord Genuity Group raised their target price on Corcept Therapeutics from $78.00 to $130.00 and gave the company a “buy” rating in a report on Thursday, January 30th. HC Wainwright reaffirmed a “buy” rating and issued a $80.00 price objective on shares of Corcept Therapeutics in a research note on Friday, February 7th. Finally, StockNews.com downgraded Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 25th.

Corcept Therapeutics Trading Up 3.5 %

Shares of Corcept Therapeutics stock opened at $63.37 on Thursday. The company has a quick ratio of 3.64, a current ratio of 3.70 and a debt-to-equity ratio of 0.01. Corcept Therapeutics has a 12-month low of $20.84 and a 12-month high of $75.00. The company has a market capitalization of $6.64 billion, a price-to-earnings ratio of 50.29 and a beta of 0.58. The firm’s 50-day moving average price is $59.60 and its two-hundred day moving average price is $51.16.

Corcept Therapeutics (NASDAQ:CORT) last issued its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $0.26 earnings per share for the quarter, missing analysts’ consensus estimates of $0.37 by ($0.11). The firm had revenue of $181.89 million for the quarter, compared to the consensus estimate of $200.12 million. Corcept Therapeutics had a return on equity of 24.54% and a net margin of 22.35%. On average, analysts forecast that Corcept Therapeutics will post 1.36 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, insider Sean Maduck sold 20,000 shares of the firm’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $50.39, for a total transaction of $1,007,800.00. Following the completion of the transaction, the insider now owns 85,318 shares of the company’s stock, valued at approximately $4,299,174.02. This trade represents a 18.99 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Daniel N. Swisher, Jr. sold 2,200 shares of Corcept Therapeutics stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $59.46, for a total transaction of $130,812.00. The disclosure for this sale can be found here. Insiders have sold 26,600 shares of company stock worth $1,399,576 in the last 90 days. Insiders own 20.50% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Capital Performance Advisors LLP bought a new stake in shares of Corcept Therapeutics in the 3rd quarter valued at about $25,000. Kestra Investment Management LLC bought a new stake in Corcept Therapeutics in the fourth quarter valued at approximately $27,000. Canada Pension Plan Investment Board acquired a new stake in Corcept Therapeutics during the 4th quarter valued at approximately $40,000. National Bank of Canada FI acquired a new stake in Corcept Therapeutics during the 4th quarter valued at approximately $42,000. Finally, USA Financial Formulas bought a new position in Corcept Therapeutics during the 4th quarter worth approximately $54,000. 93.61% of the stock is owned by institutional investors.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.